Some notes from this morning's conference call with new CEO Stephane Unwin and new CSO, Robert Hayes
Stephane Unwin
is conscious that communications are sometimes too technical for the average shareholder and is aiming to” simplify the message”
has committed to holding further conference calls to enhance communication with shareholders
a replacement Chair is being sought - someone with suitable commercial/international experience
aiming for animal efficacy data by December/January
believes that PYC is entering the stage where its science is sufficiently advanced for milestone collaborations to occur
is very confident that PYC will land a deal; says it’s just a question of when
would consider it “a failure” if PYC didn’t land two transformational deals over the next 12 months
Robert Hayes
first paper for publication is in final draft and intends to submit this to a respected journal this month
second paper (impact on tumour in a mouse xenograft model) to be submitted by the beginning of next year
says that there has been a high level of enthusiasm shown by bigger companies in PYC’s technology
says he is “very pleased” with the Genentech collaboration and that this program is progressing “better than I thought”.
wants to derisk the single iMYC program by progressing at least one further candidate. Intends to have one research proposal ready by the end of this year and another ready early next year
wants to outsource “a lot of stuff” to CROs so PYC can focus on moving development forward
mentions that intracellular targets are shaping up as the new “hot space” for pharma
points to a recent collaborative deal signed by Amgen with a small Canadian company (see link below)
comments that since first encountering PYC through his work at J & J, he has considered PYC to have the best potential cell-penetrating tech (albeit “green” at the time) as no techs match its broad applicability. He says that he still thinks PYC’s tech is ahead of its competitors, and if he didn’t, he wouldn't have joined the company.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)